Glucose control

Do not mix or dilute insulin glargine with any other insulin or solution because glucose control will be lost and the insulin will not be effective. 

Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications the VA diabetes trial. Diabetes Care 2001 24(5) 942-5. 

Educate the patient on lifestyle modifications, including smoking cessation, diet, weight loss, and exercise. For patients with diabetes mellitus, tight glucose control should be emphasized. 

Monitor blood glucose several times daily in patients with CFRD or those taking systemic corticosteroids. Follow glycosylated hemoglobin levels on an outpatient basis to assess long-term glucose control. Levels may be falsely low in CF due to a shorter red blood cell half-life. 

Hyperglycemia Poor blood glucose control (in patients with... 

Intensive Blood Glucose Control (for Patients with Diabetes)... 

Patients and clinicians can evaluate blood glucose control through a combination of self-monitoring of blood glucose data and hemoglobin HbAlc testing. 

Insulin pump therapy may be used to lower blood glucose levels in any type of DM however, patients with type 1 DM are the most likely candidates for this form of treatment. Use of an insulin pump may improve blood glucose control, reduce wide fluctuations in blood glucose levels, and allow individuals to... 

Is the patient taking any medications that may affect blood glucose control ... 

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 837-853. 

The effect of pH on skin permeability, accumulation, and penetration was studied for some important drugs such as insulin for glucose control [175], acyclovir for HIV-related conditions [176] and 5-fluorouracil for cancer treatment [177],... 

Regular insulin has a relatively slow onset of action when given subcutaneously, requiring injection 30 minutes prior to meals to achieve optimal postprandial glucose control and to prevent delayed postmeal hypoglycemia. 

However, most patients are not sufficiently predictable in their schedule and food intake to allow tight glucose control with this approach. If the fasting glucose in the morning is too high, the evening NPH dose may be moved to bedtime (now three total injections per day). This may provide sufficient intensification of therapy for some patients. 

Orlistat induces weight loss by lowering dietary fat absorption, and it also improves lipid profiles, glucose control, and other metabolic markers. Soft stools, abdominal pain or colic, flatulence, fecal urgency, and/or incontinence occur in 80% of individuals, are mild to moderate in severity, and improve after 1 to 2 months of therapy. Orlistat interferes with the absorption of fat-soluble vitamins and cyclosporine. 

Figure 9 Schematic representation of the glucose-controlled insulin release using poly(DMA-EMA-co-EAAm).

Sugars can react with proteins to form, among others, hemoglobin Aic, a measure of blood glucose control over time. 

---